Stock Detail
MEDIVATION INC
Biotechnology
MDVN @ Yahoo Finance | MDVN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $42.21 | $43.55 | $0.56 | 1.34% | 0.00 | $41.65 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $41.41 | $40.67 | 843,984 | 1.47B | 882,450 | -12.75 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 45.02 | 43.61 | 42.14 | 40.73 | 39.26 |
Stock Profile
Medivation, Inc., a biopharmaceutical company, engages in the acquisition, research, and development of various medical technologies. It develops small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and Hormone-Refractory Prostate Cancer. The company develops Dimebon for the treatment of Alzheimer's disease, which is in controlled Phase 2 efficacy study; Dimebon for the treatment of Huntington's disease, which is in a Phase 1-2a study; and proprietary small molecule MDV3100 for Hormone-Refractory Prostate Cancer. The company was founded in 2003 and is based in San Francisco, California.